ESMO 2025: Adjuvant Cemiplimab Improves Outcomes in High-Risk Cutaneous SCC

At the ESMO 2025 Congress in Berlin, Danny Rischin, MD, from the Peter MacCallum Cancer Centre, presented results from the phase III C-POST trial. In patients with high-risk cutaneous squamous cell carcinoma (SCC) after surgery and radiotherapy, adjuvant cemiplimab reduced the risk of recurrence or death by 68% compared with placebo. The treatment showed a consistent safety profile and supports cemiplimab as a new standard of care in this setting.